Last Updated: August 9, 2026

Details for Patent: 11,091,459


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 11,091,459 protect, and when does it expire?

Patent 11,091,459 protects ZEJULA and AKEEGA and is included in three NDAs.

This patent has fifteen patent family members in thirteen countries.

Summary for Patent: 11,091,459
Title:Niraparib compositions
Abstract:The present invention relates to compositions comprising the compound niraparib, in particular certain solid forms of niraparib.
Inventor(s):George Wu, John Chaber, Arlene E. McKeown, Jennifer R. Foley
Assignee: Merck Sharp and Dohme LLC , Tesaro Inc
Application Number:US16/584,401
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 11,091,459
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form;
Patent landscape, scope, and claims:

error: insufficient information

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 11,091,459

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Glaxosmithkline ZEJULA niraparib tosylate CAPSULE;ORAL 208447-001 Mar 27, 2017 DISCN Yes No ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
Janssen Biotech AKEEGA abiraterone acetate; niraparib tosylate TABLET;ORAL 216793-001 Aug 11, 2023 RX Yes No ⤷  Start Trial ⤷  Start Trial Y Y ⤷  Start Trial
Janssen Biotech AKEEGA abiraterone acetate; niraparib tosylate TABLET;ORAL 216793-002 Aug 11, 2023 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y Y ⤷  Start Trial
Glaxosmithkline ZEJULA niraparib tosylate TABLET;ORAL 214876-001 Apr 26, 2023 RX Yes No ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
Glaxosmithkline ZEJULA niraparib tosylate TABLET;ORAL 214876-002 Apr 26, 2023 RX Yes No ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
Glaxosmithkline ZEJULA niraparib tosylate TABLET;ORAL 214876-003 Apr 26, 2023 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 11,091,459

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2018246214 ⤷  Start Trial
Australia 2021245223 ⤷  Start Trial
Brazil 112019020211 ⤷  Start Trial
Canada 3058375 ⤷  Start Trial
China 110944638 ⤷  Start Trial
Eurasian Patent Organization 201992177 ⤷  Start Trial
European Patent Office 3600314 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.